Vicarious Surgical Inc. RBOT
0.01 USD -0.01 (-46.67%)
At closeOct 30, 2026, 4:00 PM EDT
1.98 +1.97 +24,650.00%
After hours · Oct 30, 4:00 PM ET
0.12 Day range 0.12
0.001 52-week range 5.18
- YTD
- -99.63%
- 1 year
- -99.85%
Analyst view
Price target (mean) 11.75 +146775.0% upside
Now 0.008
- Target (low)
- 10.50
- Target (mean)
- 11.75
- Target (high)
- 13.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy0
- Buy1
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -2.69 | -2.97 – -2.35 | -2.10 | -28.1% | 0 | 0.0% | 3 |
| Next quarter | -3.16 | -3.45 – -2.87 | -2.70 | -17.0% | 0 | 0.0% | 2 |
| Current year | -11.02 | -11.28 – -10.65 | -15.60 | +29.4% | 0 | 0.0% | 3 |
| Next year | -9.53 | -11.58 – -7.08 | -11.02 | +13.6% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Mar 5, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Dec 4, 2023 | Morgan Stanley | Initiated | — | Equal-Weight |
| Nov 14, 2023 | BTIG | Downgrade | Buy | Neutral |
| Nov 14, 2023 | Canaccord Genuity | Downgrade | Buy | Hold |
| May 31, 2023 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 18, 2022 | BTIG | Maintained | — | Buy |
| May 10, 2022 | Piper Sandler | Maintained | — | Neutral |
| Mar 4, 2022 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 4, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Jan 7, 2022 | Credit Suisse | Initiated | — | Outperform |
| Dec 7, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Nov 5, 2021 | Canaccord Genuity | Initiated | — | Buy |
| Oct 18, 2021 | BTIG | Initiated | — | Buy |
| Oct 7, 2021 | Piper Sandler | Initiated | — | Overweight |